NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ICG administration, ICG administration, ICG administration, ICG administration.
- Who it may be relevant to
- Registry conditions: Dermatofibrosarcoma Protuberans (DFSP), Skin Squamous Cell Carcinoma. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Near-infrared Fluorescence Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose Second Window Indocyanine Green Technique: a Multicenter Randomized Controlled Trial
Overview
This research study will evaluate how near-infrared fluorescence (NIRF) imaging with low-dose second window indocyanine green (ICG) can assist in the radical resection and pathologic diagnosis of malignant soft tissue sarcoma, such as dermatofibrosarcoma protuberans (DFSP) and skin squamous cell carcinoma (sSCC) during surgery.
Detailed description
To improve the accuracy of radical resection by reducing the risk of missed diagnosis of positive margin, this study will explore clinical application of near-infrared fluorescence imaging with modified low-dose SWIG technique in guiding radical resection of malignant soft tissue tumor. The investigators conduct a multi-center, multi-subgroup, prospective randomized controlled trial. The participants will be first stratified according to histological type involving dermatofibrosarcoma protuberans (DFSP) and skin squamous cell carcinoma (sSCC). The patients with DFSP or sSCC will be then randomly assigned to three groups. Patients in the control group will not receive ICG administration. The ICG was injected intravenously 24 hours before surgery, at a dose of 0.25 mg/kg in the first experimental group and 25 mg/patient in the second experimental group, respectively. The patients in the control groups will undergo traditional assessment of surgical margins.The patients in the experimental groups, on the other hand, will be scheduled to intraoperative near-infrared fluorescence imaging to scan gross tumor, tumor bed and cross-sectional specimen. The 2-year local recurrence rate will be regarded as primary outcome. The number of positive margins will be compared among groups. The investigators will also calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence intervals based on fluorescent signal of tumor bed in the experimental groups.
Interventions
- Drug ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group. - Drug ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group. - Drug ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group - Drug ICG administration
The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
Primary outcome measures
- 2-year local recurrence rate [Time frame: up to 24 months]
Secondary outcome measures (3)
- number of positive margins [Time frame: through study completion, an average of 2 years]
- sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) [Time frame: through study completion, an average of 2 years]
- Adverse effects [Time frame: through study completion, an average of 2 years]
Eligibility criteria
Inclusion criteria
- Patients with DFSPs or sSCC in heads, extremities or trunk
Exclusion criteria
- seafood/iodine allergy
- hyperthyroidism
- pregnancy
- myasthenia gravis
- acute severe hypertension
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06610071 · CFH2024-2-4043